FDA Orange Book · active-ingredient family
Alvimopan
Alvimopan: 1 brand, 3 generics; first approved May 20, 2008; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 3 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
1
Generics (ANDA)
3
Listed patents
1
Next patent expiry
Feb 12, 2030
in 3 yr 6 mo
Brand (NDA) products
Originator applications
- ENTEREGRLDCUBIST PHARMSNDA 0217752008
Approved strengths under this FDA application. Strength Dosage form Route Status TE 12MG CAPSULE ORAL Discontinued —
Generic (ANDA) products (3)
Abbreviated applications
- ALVIMOPANHIKMAANDA 2177532023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 12MG CAPSULE ORAL Rx AB - ALVIMOPANPH HEALTHANDA 2168432023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 12MG CAPSULE ORAL Rx AB - ALVIMOPANRSWATSON LABS TEVAANDA 2082952019
Approved strengths under this FDA application. Strength Dosage form Route Status TE 12MG CAPSULE ORAL Rx AB
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 8946262 | in 3 yr 6 mo | U-1655 |
Approval history
FDA approval span
First approval
18 yr 6 mo ago
Most recent approval
3 yr ago
Approvals span 2008–2023 across 4 FDA applications.
Brand (NDA) 125%
Generic (ANDA) 375%
Alvimopan: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
